NEWS
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Barinthus Biotherapeutics announced plans to prioritize its pipeline, focusing on VTP-300 for Chronic Hepatitis B (CHB) and VTP-1000 for celiac disease, following positive interim data from ongoing Phase 2 trials. The company will restructure, reducing its workforce by 25%, and expects to extend its cash runway to Q2 2026. VTP-300 data showed significant reductions in Hepatitis B surface antigen levels, while pre-clinical data for VTP-1000 in celiac disease were promising. The Phase 1 trial for VTP-1000 is set to begin in Q3 2024, and the ongoing Phase 1 trial of VTP-850 in prostate cancer will be completed.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1195Followers
74Following
8478Visitors
Follow